vaginal mesh

Laparoscopic excision of vaginal mesh found effectiveWhile most clinicians remove vaginal mesh through the vagina, employing laparoscopy is feasible and safe, especially when there is limited visualization through the vagina, according to a case series presented at the 46th AAGL Global Congress on Minimally Invasive Gynecology.
Use of biologic grafts in pelvic organ prolapse surgery
Use of biologic grafts in pelvic organ prolapse surgeryPelvic organ prolapse is a very prevalent condition, affecting up to half of all women over 50 years old. Biological grafts may be useful in certain patients but long-term trials are needed to guide their proper use.
Urogynecologists speak: FDA reclassification welcomeA January 4th action by the US Food and Drug Administration (FDA) reclassified transvaginal mesh implants for pelvic organ prolapse (POP) as class III (or high-risk) medical devices requiring premarket approval application (PMA).
FDA reclassifies mesh for POPSurgical mesh for pelvic organ prolapse (POP) is a class III or high-risk medical device requiring premarket approval application (PMA) following new action by the Food and Drug Administration (FDA).
Vaginal reconstructive surgery: A case for and against mesh useDo the benefits of transvaginal mesh outweigh its risks or should use of the product be confined to randomized trials until until more robust clinical data are available?
Best of AUA 2014: Female Urology/Incontinence/UrodynamicsAdonis K. Hijaz, MD, presents the take home messages on female urology/incontinence/urodynamics from the AUA annual meeting in Orlando, FL, including studies on mesh outcomes and the overactive bladder treatment mirabegron (Myrbetriq).
Vaginal mesh complications and miscommunicationsBetter communication between surgeons and pathologists will help to inform understanding of vaginal mesh complications.